

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

# PHA 5127

## First Exam Fall 2012

On my honor, I have neither given nor received unauthorized aid in doing this assignment.

---

Name

### Question Set/Points

- I. 30 pts
- II. 20 pts
- III. 20 pts
- IV. 15 pts
- V. 25 pts
- VI. 20 pts
- VII. 15 pts
- VIII. 20 pts
- IX. 35 pts

TOTAL: 200 pts

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

**Question Set I (True or False)**

(30 points)

**True (A) or False (B). On the bubble sheet mark A for true or B for false. Assume passive diffusion as the driving force for distribution.**

- 1:    T    F    Assume a drug that is eliminated through metabolism. The drug's plasma concentration decreases by 4 ng/ml every 2 hours. It is likely that the enzymes involved in the metabolism are saturated.
  
- 2:    T    F    Assume a drug eliminated through enzymatic metabolism. The drug's plasma concentration decreases by 4 ng/ml every 2 hours. The elimination rate constant describing this metabolism will have the unit: 1/hr
  
- 3:    T    F    The rate at which a lipophilic drug, of low molecular weight that is not an acid nor a base, is taken up by tissues will significantly be related to the blood flow through those tissues.
  
- 4:    T    F    The rate at which a lipophilic drug that is not an acid nor a base is taken up by fat tissue is likely to be faster than the rate at which it is taken up by the kidney.
  
- 5:    T    F    The same dose of a drug is given either as a solution or in form of a slow dissolving crystal suspension. The solution will have to be given more often during the day.
  
- 6:    T    F    Plasma can be prepared by letting the collected patient's blood clot. The resulting supernatant is called plasma.

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

**Question Set II (20 points)**

**True (A) or False (B). On the bubble sheet mark A for true or B for false. Consider the lipophilic drug A and a drug B which is even more lipophilic. Both do not show any affinity to transporters (Ficks law applies), show the same tissue and plasma protein binding.**

7: T F Drug B will enter the liver faster.

8: T F Drug A will be unable to enter the interstitial fluid.

9: T F Both drugs will have the same volume of distribution.

10: T F Drug B is more likely to show permeability limited tissue uptake.

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

**Question Set III**

(20 points)

11: Listed in the Table are two properties of acidic drug molecules:

- the fraction unionized at  $\text{pH}=7.4$  and
- the partition coefficient of the unionized form.

DRUG	Fraction Unionized at $\text{pH}=7.4$	Partition Coefficient of Unionized form	Molecular Weight (Dalton)
1	0.5	2.1	240
2	0.91	0.07	290
3	0.074	10	320
4	0.72	0.005	456

Select the correct rank order with which drugs 1-4 will enter brain tissue. Assume that the drugs are not subject to transporters at the blood-brain barrier.

- A: 1 slower than 2 slower than 3 slower than 4
- B: 1 slower than 3 slower than 2 slower than 4
- C: 4 slower than 2 slower than 3 slower than 1
- D: 4 slower than 2 slower than 1 slower than 3
- E: 3 slower than 1 slower than 4 slower than 2

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

**Question Set IV (True or False)**

(15 points)

**True (A) or False (B). On the bubble sheet mark *A* for true or *B* for false. Assume no active transport.**

Assume the same dose of penicillin G is given to patients as iv bolus injection (as solution in saline), intramuscular (i.m.) oily injection or orally.

12:    T    F    Giving the drug orally will result in a much smaller AUC than after i.m. and iv injection.

13:    T    F    Penicillin G is stable in the gastro-intestinal tract.


14:    T    F    iv injections allow a less frequent dosing.

Name: \_\_\_\_\_


UFID#: \_\_\_\_\_

**Question Set V (True or False)**

(25 points)



**Drug A**



**Drug B**

**True (A) or False (B). On the bubble sheet mark A for true or B for false**

15: T F Drug A's rate of elimination is affected by the amount of drug in the body.

16: T F Drug B's elimination rate constant has the unit "ng/ml".

17: T F For Drug A, the fraction of drug eliminated per hour is constant.

18: T F Drug B's concentration-time profile might be explained by saturated metabolic enzymes.

19: T F The half-life of Drug B depends on the concentration that should be cut into half.

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Question Set VI

(20 points)

20: 200 mg of Drug A was administered to a patient through iv bolus injection. A plasma drug concentration of 0.78 mg/L was measured after 2 hours. A plasma drug concentration of 0.16 mg/L was measured after 8 hours. The drug's distribution is instantaneous.

Assuming a **first** order process, calculate the elimination rate constant

- A:  $0.16 \text{ h}^{-1}$
- B:  $0.16 \text{ mg/ (L*h)}$
- C:  $0.264 \text{ mg/ (L*h)}$
- D:  $0.264 \text{ h}^{-1}$
- E: None of the above

21: 200 mg of Drug A was administered to a patient through i.v bolus injection. A plasma drug concentration of 0.78 mg/L was measured after 2 hours. A plasma drug concentration of 0.16 mg/L was measured after 4 hours. The drug's distribution is instantaneous.

Assuming a **zero** order process, calculate the initial drug concentration

- A: 1.32 mg/L
- B: 1.32 L
- C: 1.4 mg/L
- D: None of the above

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Question Set VII

(15 points)

A drug (lipophilic, unionized, low molecular weight) is showing in average a pronounced binding to plasma proteins of 99%. Between-subject variability of protein binding is pronounced. 1000mg of the drug is given as IV bolus injection to two patients. **Patient 1 has a much stronger plasma protein binding** for the drug (99.995%) than the second patient (99.99%). The tissue binding is the same in both patients and is equal to 90%.

Based on the given information please indicate whether **patient 1** will have a larger ( $\uparrow$ ), smaller ( $\downarrow$ ) identical ( $\leftrightarrow$ ) value than patient 2 for:

- total initial total plasma drug concentration ( $C_0$ ),
- free initial total plasma drug concentration (**free  $C_0$** ),
- $f_u$
- $V_d$

22 :

A:  $C_0 \uparrow$ , free  $C_0 \uparrow$ ,  $f_u \downarrow$ ,  $V_d \downarrow$

B:  $C_0 \downarrow$ , free  $C_0 \leftrightarrow$ ,  $f_u \downarrow$ ,  $V_d \uparrow$

C:  $C_0 \uparrow$ , free  $C_0 \downarrow$ ,  $f_u \downarrow$ ,  $V_d \downarrow$

D:  $C_0 \uparrow$ , free  $C_0 \uparrow$ ,  $f_u \uparrow$ ,  $V_d \leftrightarrow$

E: none of above combinations.



Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Question Set VIII

(20 points)

Assume a drug is substrate of a specific transport protein. What of the following statements are **True (A)** or **False (B)**. **On the bubble sheet mark A for true or B for false**

- 23:    T    F    Transporters do not use energy.
- 24:    T    F    Transporters only eliminate drugs from the body.
- 25:    T    F    Transporters are only present in liver and kidney.
- 26:    T    F    Transporters are saturable.
- 27:    T    F    Transporters work often in conjunction with enzymes.

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Question Set IX

(35 points)

- 28: T F Free drug concentrations are assumed to be the same in plasma and tissues, when the distribution is assumed to be instantaneous.
- 29: T F For a drug that shows permeability controlled uptake into all tissues, total drug concentrations are always higher in the plasma than in tissues.
- 30: T F When the  $V_d$  of a drug is 41L; we can conclude that the drug has no plasma protein binding or tissue binding.
- 31: T F A fast absorption might allow less frequent dosing.
- 32: T F A slower absorption might be advantageous for a drug with a narrow therapeutic window.
- 33: T F The Fick's law is:  $dq/dt = D * K * (C_{plasma} - C_{tissue})/h$ . The k in the equation denotes the first order elimination rate constant.
- 34: T F Concentrations in plasma are of relevance for the drug therapy as they are generally identical to concentrations at the target site.

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

## Useful Pharmacokinetic Equations

### Symbols

D = dose  
 $\tau$  = dosing interval  
 CL = clearance  
 Vd = volume of distribution  
 $k_e$  = elimination rate constant  
 $k_a$  = absorption rate constant  
 F = fraction absorbed (bioavailability)  
 $K_0$  = infusion rate  
 T = duration of infusion  
 C = plasma concentration

### General

#### Elimination rate constant

$$k_e = \frac{CL}{Vd} = \frac{\ln\left(\frac{C_1}{C_2}\right)}{(t_2 - t_1)} = \frac{\ln C_1 - \ln C_2}{(t_2 - t_1)}$$

#### Half-life

$$t_{1/2} = \frac{0.693 \cdot Vd}{CL} = \frac{\ln(2)}{k_e} = \frac{0.693}{k_e}$$

### Intravenous bolus

#### Initial concentration

$$C_0 = \frac{D}{Vd}$$

#### Plasma concentration (single dose)

$$C = C_0 \cdot e^{-k_e \cdot t}$$

#### Plasma concentration (multiple dose)

$$C = \frac{C_0 \cdot e^{-k_e \cdot t}}{(1 - e^{-k_e \cdot \tau})}$$

#### Peak (multiple dose)

$$C_{\max} = \frac{C_0}{(1 - e^{-k_e \cdot \tau})}$$

#### Trough (multiple dose)

$$C_{\min} = \frac{C_0 \cdot e^{-k_e \cdot \tau}}{(1 - e^{-k_e \cdot \tau})}$$

#### Average concentration (steady state)

$$\bar{C}_{p_{ss}} = \frac{D}{CL \cdot \tau}$$

### Oral administration

#### Plasma concentration (single dose)

$$C = \frac{F \cdot D \cdot k_a}{Vd(k_a - k_e)} \cdot (e^{-k_e \cdot t} - e^{-k_a \cdot t})$$

#### Time of maximum concentration (single dose)

$$t_{\max} = \frac{\ln\left(\frac{k_a}{k_e}\right)}{(k_a - k_e)}$$

#### Plasma concentration (multiple dose)

$$C = \frac{F \cdot D \cdot k_a}{Vd(k_a - k_e)} \cdot \left( \frac{e^{-k_e \cdot t}}{(1 - e^{-k_e \cdot \tau})} - \frac{e^{-k_a \cdot t}}{(1 - e^{-k_a \cdot \tau})} \right)$$

#### Time of maximum concentration (multiple dose)

$$t_{\max} = \frac{\ln\left(\frac{k_a \cdot (1 - e^{-k_e \cdot \tau})}{k_e \cdot (1 - e^{-k_a \cdot \tau})}\right)}{(k_a - k_e)}$$

#### Average concentration (steady state)

$$\bar{C} = \frac{F \cdot D}{CL \cdot \tau}$$

#### Clearance

$$Cl = \frac{Dose \cdot F}{AUC}$$

$$Cl = k_e \cdot V_d$$

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Constant rate infusion

#### Plasma concentration (during infusion)

$$C = \frac{k_0}{CL} \cdot (1 - e^{-k_e \cdot t})$$

#### Plasma concentration (steady state)

$$C = \frac{k_0}{CL}$$

#### Calculated clearance (Chiou equation)

$$CL = \frac{2 \cdot k_0}{(C_1 + C_2)} + \frac{2 \cdot Vd \cdot (C_1 - C_2)}{(C_1 + C_2) \cdot (t_2 - t_1)}$$

### Short-term infusion

#### Peak (single dose)

$$C_{\max(1)} = \frac{D}{CL \cdot T} \cdot (1 - e^{-k_e \cdot T})$$

#### Trough (single dose)

$$C_{\min(1)} = C_{\max(1)} \cdot e^{-k_e(\tau - T)}$$

#### Peak (multiple dose)

$$C_{\max} = \frac{D}{CL \cdot T} \cdot \frac{(1 - e^{-k_e \cdot T})}{(1 - e^{-k_e \cdot \tau})}$$

#### Trough (multiple dose)

$$C_{\min} = C_{\max} \cdot e^{-k_e(\tau - T)}$$

#### Calculated elimination rate constant

$$k_e = \frac{\ln\left(\frac{C_{\max}^*}{C_{\min}^*}\right)}{\Delta t}$$

with  $C_{\max}^*$  = measured peak and  $C_{\min}^*$  = measured trough,  
measured over the time interval  $\Delta t$

#### Calculated peak

$$C_{\max} = \frac{C_{\max}^*}{e^{-k_e \cdot t^*}}$$

with  $C_{\max}^*$  = measured peak, measured at time  $t^*$  after the end of the infusion

#### Calculated trough

$$C_{\min} = C_{\min}^* \cdot e^{-k_e \cdot t^*}$$

with  $C_{\min}^*$  = measured trough, measured at time  $t^*$  before the start of the next infusion

#### Calculated volume of distribution

$$Vd = \frac{D}{k_e \cdot T} \cdot \frac{(1 - e^{-k_e \cdot T})}{[C_{\max} - (C_{\min} \cdot e^{-k_e \cdot T})]}$$

#### Calculated recommended dosing interval

$$\tau = \frac{\ln\left(\frac{C_{\max(\text{desired})}}{C_{\min(\text{desired})}}\right)}{k_e} + T$$

#### Calculated recommended dose

$$D = C_{\max(\text{desired})} \cdot k_e \cdot V \cdot T \cdot \frac{(1 - e^{-k_e \cdot \tau})}{(1 - e^{-k_e \cdot T})}$$

### Two-Compartment-Body Model

$$C = a \cdot e^{-\alpha t} + b \cdot e^{-\beta t}$$

$$AUC_{\infty} = a / \alpha + b / \beta$$

$$Vd_{\text{area}} > Vd_{\text{ss}} > Vc$$

#### Creatinine Clearance

$$CL_{\text{creat}}(\text{male}) = \frac{(140 - \text{age}) \cdot \text{weight}}{72 \cdot Cp_{\text{creat}}}$$

$$CL_{\text{creat}}(\text{female}) = \frac{(140 - \text{age}) \cdot \text{weight}}{85 \cdot Cp_{\text{creat}}}$$

With weight in kg, age in years, creatinine plasma conc. in mg/dl and  $CL_{\text{creat}}$  in ml/min

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### **$K_e$ for aminoglycosides**

$$K_e = 0.00293(\text{CrCL}) + 0.014$$

### **Metabolic and Renal Clearance**

$$E_H = \frac{Cl_{int} \cdot fu_b}{Q_H + Cl_{int} \cdot fu_b}$$

$$Cl_H = E_H \cdot Q_H = \frac{Q_H \cdot Cl_{int} \cdot fu_b}{Q_H + Cl_{int} \cdot fu_b}$$

$$F_H = \frac{Q_H}{Q_H + Cl_{int} \cdot fu_b}$$

$$Cl_{ren} = \text{RBF} \cdot E = \text{GFR} \cdot \frac{C_{in} - C_{out}}{C_{in}}$$

$$Cl_{ren} = \frac{\text{rate of excretion}}{\text{plasma concentration}}$$

$$Cl_{ren} = fu \cdot \text{GFR} + \left[ \frac{\text{Rate of secretion} - \text{Rate of reabsorption}}{\text{Plasma concentration}} \right]$$

$$Cl_{ren} = \frac{\text{Urine flow} \cdot \text{urine concentration}}{\text{Plasma concentration}}$$

### **Ideal Body Weight**

#### **Male**

IBW = 50 kg + 2.3 kg for each inch over 5ft in height

#### **Female**

IBW = 45.5 kg + 2.3 kg for each inch over 5ft in height

#### **Obese**

ABW = IBW + 0.4\*(TBW-IBW)

### **Volume of Distribution**

$$V = V_p + V_t \cdot K_p$$

$$V = V_p + V_t \cdot \frac{fu}{fu_t}$$

### **Clearance**

$$Cl = \frac{\text{Dose}}{\text{AUC}}$$

$$Cl = k_e \cdot V_d$$

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

### Constant rate infusion

#### Plasma concentration (during infusion)

$$C = \frac{k_0}{CL} \cdot (1 - e^{-k_e \cdot t})$$

#### Plasma concentration (steady state)

$$C = \frac{k_0}{CL}$$

#### Calculated clearance (Chiou equation)

$$CL = \frac{2 \cdot k_0}{(C_1 + C_2)} + \frac{2 \cdot Vd \cdot (C_1 - C_2)}{(C_1 + C_2) \cdot (t_2 - t_1)}$$

### Short-term infusion

#### Peak (single dose)

$$C_{\max(1)} = \frac{D}{CL \cdot T} \cdot (1 - e^{-k_e \cdot T})$$

#### Trough (single dose)

$$C_{\min(1)} = C_{\max(1)} \cdot e^{-k_e(\tau - T)}$$

#### Peak (multiple dose)

$$C_{\max} = \frac{D}{CL \cdot T} \cdot \frac{(1 - e^{-k_e \cdot T})}{(1 - e^{-k_e \cdot \tau})}$$

#### Trough (multiple dose)

$$C_{\min} = C_{\max} \cdot e^{-k_e(\tau - T)}$$

#### Calculated elimination rate constant

$$k_e = \frac{\ln\left(\frac{C_{\max}^*}{C_{\min}^*}\right)}{\Delta t}$$

with  $C_{\max}^*$  = measured peak and  $C_{\min}^*$  = measured trough,  
measured over the time interval  $\Delta t$

#### Calculated peak

$$C_{\max} = \frac{C_{\max}^*}{e^{-k_e \cdot t^*}}$$

with  $C_{\max}^*$  = measured peak, measured at time  $t^*$  after the end of the infusion

#### Calculated trough

$$C_{\min} = C_{\min}^* \cdot e^{-k_e \cdot t^*}$$

with  $C_{\min}^*$  = measured trough, measured at time  $t^*$  before the start of the next infusion

#### Calculated volume of distribution

$$Vd = \frac{D}{k_e \cdot T} \cdot \frac{(1 - e^{-k_e \cdot T})}{[C_{\max} - (C_{\min} \cdot e^{-k_e \cdot T})]}$$

#### Calculated recommended dosing interval

$$\tau = \frac{\ln\left(\frac{C_{\max(\text{desired})}}{C_{\min(\text{desired})}}\right)}{k_e} + T$$

#### Calculated recommended dose

$$D = C_{\max(\text{desired})} \cdot k_e \cdot V \cdot T \cdot \frac{(1 - e^{-k_e \cdot \tau})}{(1 - e^{-k_e \cdot T})}$$

### Two-Compartment-Body Model

$$C = a \cdot e^{-\alpha t} + b \cdot e^{-\beta t}$$

$$AUC_{\infty} = a / \alpha + b / \beta$$

$$Vd_{\text{area}} > Vd_{\text{ss}} > Vc$$

#### Creatinine Clearance


$$CL_{\text{creat}}(\text{male}) = \frac{(140 - \text{age}) \cdot \text{weight}}{72 \cdot Cp_{\text{creat}}}$$

$$CL_{\text{creat}}(\text{female}) = \frac{(140 - \text{age}) \cdot \text{weight}}{85 \cdot Cp_{\text{creat}}}$$

With weight in kg, age in years, creatinine plasma conc. in mg/dl and  $CL_{\text{creat}}$  in ml/min

Name: \_\_\_\_\_

UFID#: \_\_\_\_\_



Name: \_\_\_\_\_

UFID#: \_\_\_\_\_

